Visionsearch was founded in 2011 and has delivered Visionsearch1 systems worldwide since 2012, including to USA, UK, Canada, Israel, Australia, Germany, Belgium, Sweden, Denmark and Serbia. The VS+ is a significantly upgraded system featuring a new custom bio amplifier, based on the success of the Visionsearch1.
The Visionsearch1 has already demonstrated the advantage of Visionsearch mfVEP technology:
- Highly reproducible results. 2ms reproducibility in latency amongst all healthy control patients and most Optic Neuritis patients in an independent study conducted in Calgary and Jerusalem (P281
- ECTRIMS 2002, P2.245 67th Meeting of the American Academy of Neurology).
- First multifocal VEP system to be successfully used in a randomized clinical trial, showing a greater magnitude response than the trial’s full-field primary endpoint (P7.208 67th Meeting of American Academy of Neurology).
The VS+ continues to offer our world leading mfVEP technology, but adds simpler wiring, reduced noise, more accurate skin impedance measurements (with handy indicators on the patient electrode unit), and more advanced analysis functions.
Legacy Visionserach1 System Undergoing Testing at the Visionsearch Office